Neoadjuvant Chemoradiotherapy With CRLX-101 and Capecitabine for Rectal Cancer

Stopped early · Phase 1/Phase 2

Conditions studied: Rectal Cancer

In brief

This trial will enroll patients with locally advanced rectal cancer (resectable and non-resectable).The phase Ib dose escalation portion of trial is designed to determine the maximum tolerated dose (MTD) of CRLX101 when combined with standard neoadjuvant therapies capecitabine (Cape) and radiation therapy (XRT). CRLX101 is a nanopharmaceutical (NP) formulation of camptothecin. These results will determine the recommended phase II dose (RP2D) for CRLX101 in this setting. The phase II portion of the trial is designed to evaluate the efficacy and safety of CRLX101 at the RP2D, when combined with capecitabine and radiation therapy prior to surgery.

Key facts

Study ID: NCT02010567
Run by: UNC Lineberger Comprehensive Cancer Center
People needed: 32
Starts: 2013-12-01
Expected to finish: 2019-06-25
Last updated by the study team: 2020-11-03

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Eastern Cooperative Oncology Group (ECOG) performance score ≤ 2
Phase Ib and II: surgical candidates, with moderate to high-risk pathologically-confirmed rectal cancer (Tumor (T) and Nodal (N) stage cT3-4N0 or cT1-4N+); clinical staging by endoscopic ultrasound (EUS) or magnetic resonance imaging (MRI) is permitted.
Phase Ib only:
Patients with metastatic rectal cancer are allowed if their primary site meets other eligibility criteria and chemoradiotherapy is recommended as initial therapy for symptom palliation by the multidisciplinary treating team
Patients with locally advanced unresectable rectal cancer are allow provided:
There is no evidence of recto-vaginal, recto-vesicular, recto-intestinal fistulization
Standard dose and schedule chemoradiotherapy is recommended as initial therapy by the multidisciplinary treating team
Age ≥18 years old
Women of childbearing potential (WOCBP) must have negative pregnancy test within 7 days prior to D1 of treatment
Recommendation to undergo concurrent chemoradiation, as determined by the treating physician
Ability to swallow oral medications
As determined by the enrolling physician or protocol designee, ability of the patient to understand and comply with study procedures for the entire length of the study
Informed consent reviewed and signed

You may not qualify if…

Patients meeting any of the following exclusion criteria will not be able to participate in this study:
Grade 2 or higher diarrhea at baseline unless deemed by the investigator to be caused by laxatives prescribed for symptomatic partial obstruction (e.g. MiraLAX®)
Not deemed a candidate for concurrent chemoradiation for medical reasons, such as uncontrolled infection (including HIV), uncontrolled diabetes mellitus or cardiac disease which, in the opinion of the treating physician, would make this protocol unreasonably hazardous for the patient.
Specific laboratory exclusion values, including:
Hemoglobin < 10.0 g/dL for males and ≤ 9.0 g/dL for females (transfusion allowed to achieve or maintain levels)
Absolute neutrophil count (ANC) < 1,500/mm3
Platelet count < 100,000/mm3
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) > 2.5 times upper level of normal (ULN)
Alkaline phosphatase > 2.5 times ULN
Total bilirubin > 1.5 times ULN
Creatinine clearance < 50 mL/min
International normalized ratio (INR) >2
Known dihydropyrimidine dehydrogenase (DPD) deficiency
History of Gilbert's syndrome
Those who require therapeutic anticoagulation with coumarin-derivative anticoagulants
Unable to provide informed consent
Receiving any other concurrent cytotoxic, biologic agent(s) or investigational agent
Patients with a "currently active" second malignancy other than non-melanoma skin cancers, non-invasive bladder cancer, "low risk" adenocarcinoma of the prostate and carcinoma in situ of the cervix. Patients are not considered to have a "currently active" malignancy if they have completed therapy and are free of disease for ≥ 2 years.
Previous pelvic radiation therapy
Prior treatment with a topoisomerase I inhibitor (i.e. irinotecan, topotecan)

Where it is running

Rocky Mountain Cancer Center — Denver, Colorado, United States
Indiana University Simon Cancer Center — Indianapolis, Indiana, United States
University of North Carolina — Chapel Hill, North Carolina, United States
Rex Cancer Center at Rex Hospital — Raleigh, North Carolina, United States
Wake Forest University Comprehensive Cancer Center — Winston-Salem, North Carolina, United States
Swedish Cancer Institute — Seattle, Washington, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.